An interim analysis of the DREAMM-8 trial showed belantamab mafodotin (Blenrep) improved progression-free survival when combined with pomalidomide (Pomalyst) and dexamethasone as second-line treatment for patients with relapsed/refractory multiple myeloma, . The drug was withdrawn from the U.S. market in 2022.
Common inherited genetic factors that predict cancer risk in the general population could also predict an . (Nature Medicine)
A study of children with sickle cell anemia showed that despite their elevated risk of infections and stroke, many . (Pediatrics)
The FDA to zanubrutinib (Brukinsa) plus obinutuzumab (Gazyva) as a third-line option in follicular lymphoma based on findings from the phase II ROSEWOOD trial.
Medtronic announced that it received FDA clearance for its .
The to include the treatment of pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
A vaccine may be able to . Could it one day be used for humans? (Yale News)
A cancer patient who was hit and dragged by a New York City bus and left partially paralyzed million by a city jury. (ABC News)
Why are more Asian-American women developing lung cancer ? (NBC News)
Bayer said it was brought by a retired postal service worker in Pennsylvania who alleged he developed non-Hodgkin lymphoma from using the company's Roundup weedkiller. (Reuters)
The U.K.'s National Health Service is (Enhertu) for patients with advanced breast cancer after the National Institute for Health and Care Excellence said its cost outweighed its benefits. (The Independent)
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/MikeBassett_188.jpg)